# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Liliʻuokalani (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET024-SYN
- Date: 2026-04-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Kealani Morrison-Takeda, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Five-week review: rhythm monitor result and anticoagulation. **S**

## History of present illness

Liliʻuokalani returns five weeks after the stroke, with a member of her ʻohana. The 30-day monitor recorded six episodes of atrial fibrillation, the longest 3 hours 10 minutes, about 3% of the time, none of which she felt. She finished 21 days of aspirin and clopidogrel two weeks ago and now takes clopidogrel alone, with no bleeding. Her home blood pressure averaged 138/82 in the week after the stroke, so losartan 25 mg was started a week after the event; her home average is now 126/76. The potassium and creatinine check two weeks after starting losartan did not happen: the member of her household who drives her was away, and she did not want to trouble anyone. She has had no new neurological symptoms and plays the piano every morning. She has begun lomilomi with a practitioner at Ke Ola Mamo, who was told about her blood thinners. **S**

| Element | Detail |
|---|---|
| Rhythm monitor | Paroxysmal atrial fibrillation: six episodes, longest 3 hours 10 minutes, burden about 3%; no symptoms |
| Antiplatelets | 21 days of aspirin and clopidogrel completed; clopidogrel alone since |
| Home blood pressure | Average 126/76 mmHg on losartan 25 mg |
| Missed test | Potassium and creatinine two weeks after losartan not done; no ride |
| Function | Plays the piano daily; no new symptoms |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Negative | No new weakness, numbness, speech, vision or balance problem |
| Cardiovascular | Negative | No palpitations, breathlessness or fainting |
| Hematologic | Negative | No bruising, bleeding gums, black stools or blood in the urine |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |

4 systems reviewed. **S**

## Current medications

- Atorvastatin 40 mg oral tablet, one tablet daily **S**
- Losartan 25 mg oral tablet, one tablet daily **S**
- Apixaban 5 mg oral tablet, one tablet twice daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/78 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 57.8 kg; BMI 22.6 kg/m². All vital signs are synthetic.

Sodium: 138 mmol/L; Potassium: 4.5 mmol/L; Creatinine: 0.86 mg/dL; eGFR (CKD-EPI 2021): 69 mL/min/1.73 m²; Glucose: 96 mg/dL; Hemoglobin: 12.7 g/dL; Platelets: 228 10*3/uL; Total cholesterol: 138 mg/dL; LDL cholesterol: 64 mg/dL; HDL cholesterol: 56 mg/dL; Triglycerides: 92 mg/dL; ALT: 22 U/L. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 0.82 mg/dL at baseline, 0.86 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 73 mL/min/1.73 m² at baseline, 69 mL/min/1.73 m² at this visit **S**
- Glucose: 98 mg/dL at baseline, 96 mg/dL at this visit **S**
- Hemoglobin: 12.8 g/dL at baseline, 12.7 g/dL at this visit **S**
- Platelets: 232 10*3/uL at baseline, 228 10*3/uL at this visit **S**
- Total cholesterol: 214 mg/dL (high) at baseline, 138 mg/dL at this visit **S**
- LDL cholesterol: 132 mg/dL (high) at baseline, 64 mg/dL at this visit **S**
- HDL cholesterol: 58 mg/dL at baseline, 56 mg/dL at this visit **S**
- Triglycerides: 120 mg/dL at baseline, 92 mg/dL at this visit **S**
- ALT: 16 U/L at baseline, 22 U/L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 130/78, pulse 74 and regular; weight 57.8 kg |
| Cardiovascular | Regular rhythm; no murmur |
| Neurological | Speech fluent; no drift; normal fine finger movements; normal gait |
| Skin | No bruising |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Paroxysmal atrial fibrillation, the likely source of the stroke** (I48.0). CHA2DS2-VASc 6 (age 75 or older, stroke, hypertension, female sex); HAS-BLED 2. An anticoagulant prevents far more strokes than antiplatelets in atrial fibrillation, and the bleeding risk is acceptable. The infarct was small and five weeks old, so it is safe to start now. Full-dose apixaban: she meets only one of the three dose-reduction criteria (age 80 or older, weight 60 kg or less, creatinine 1.5 mg/dL or more). Creatinine clearance about 49 mL/min. **S**
   - Stop clopidogrel today.
   - Start apixaban 5 mg twice daily, about 12 hours apart, without missing doses.
   - Avoid aspirin, ibuprofen and naproxen; acetaminophen for pain.
   - Blood count and kidney function about every five months.
   - Tell any practitioner who gives lomilomi or other bodywork that she takes apixaban, and ask for gentle pressure.
2. **Minor ischemic stroke** (I63.412). Cardioembolic from atrial fibrillation, with a small carotid plaque. LDL 64 mg/dL on atorvastatin 40 mg, below the goal of 70. **S**
   - Continue atorvastatin 40 mg; lipid panel in three to four months.
3. **Hypertension** (I10). Home average 126/76 and clinic 130/78 on losartan 25 mg; potassium 4.5 mmol/L and creatinine 0.86 mg/dL today. **S**
   - Continue losartan 25 mg.
   - Laboratory tests at clinic visits, or at home by the clinic's nurse, so that no separate trip is needed.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure in the clinic and at home (target below 130/80 mmHg) and weight | Every visit | Completed today | 130/78 mmHg; home average 126/76; 57.8 kg |
| Laboratory | Potassium and creatinine after starting an angiotensin receptor blocker | About two weeks after starting, then every six months | Deferred | The check due two weeks after losartan was started was missed: the member of her household who drives her was away, and she did not ask anyone else. Today, four weeks after the start, potassium is 4.5 mmol/L and creatinine 0.86 mg/dL (eGFR 69), both normal, so no harm resulted. Corrective action: tests drawn at clinic visits, or at home by the clinic's nurse |
| Imaging | ECG and prolonged rhythm monitoring for atrial fibrillation | ECG at baseline; at least 30 days of monitoring within six months of the event | Completed today | 30 days of monitoring: paroxysmal atrial fibrillation, six episodes, burden about 3% |
| Medication safety | Antithrombotic therapy and adherence | Every visit | Completed today | 21 days of dual antiplatelets completed; clopidogrel stopped today; apixaban 5 mg twice daily started |
| Laboratory | Anticoagulant safety: blood count, kidney function (creatinine clearance) and liver tests | Before starting, then about every creatinine clearance / 10 months at age 75 or older (about every five months for her) | Completed today | Before apixaban: hemoglobin 12.7 g/dL, platelets 228, creatinine 0.86 mg/dL (creatinine clearance about 49 mL/min), ALT 22 U/L |
| Laboratory | Lipid panel (LDL goal below 70 mg/dL) | Four to twelve weeks after starting a statin, then every three to twelve months | Completed today | Five weeks on atorvastatin 40 mg: LDL 64 mg/dL, total cholesterol 138, HDL 56, triglycerides 92 |
| Imaging | Carotid and intracranial vessel imaging | At the event; follow-up only for treated or moderate or greater stenosis | Not indicated | Carotid plaque under 50%; no follow-up imaging needed |
| Examination | Neurological status (NIH Stroke Scale at the event; modified Rankin Scale at 90 days) and new symptoms | With any change; modified Rankin Scale at 90 days | Completed today | No new symptoms; examination normal |
| Survey | Cognitive screen (MoCA) | After the event, again within the first year, then periodically | Up to date | MoCA 26 at the stroke clinic; repeat within the first year |
| Survey | Depression screen (PHQ-2, PHQ-9) | At the first post-stroke visit, then at least yearly | Up to date | PHQ-2 1 at the stroke clinic; PHQ-9 at three months |
| Examination | Falls risk | Every visit | Completed today | No falls; falls plan reviewed before starting an anticoagulant |
| Self-management | Tobacco, alcohol and physical activity | Every visit | Completed today | Never smoker; alcohol rarely; walks daily |
| Self-management | BE FAST and calling 911 | Every visit | Completed today | Reviewed |
| Self-management | Culturally safe care: her choices, ʻohana involvement and Native Hawaiian healing alongside clinic care | Every visit | Completed today | Lomilomi at Ke Ola Mamo by her choice, with the practitioner told about her blood thinners; the decision on apixaban was hers, with her ʻohana present |

## Goal progress

- No recurrent stroke or transient ischemic attack. In progress; target 2026-08-24. **S**
- LDL cholesterol below 70 mg/dL. Outcome by 2026-04-20: 132 to 64 mg/dL on atorvastatin 40 mg. **S**
- Blood pressure below 130/80 mmHg at home and in the clinic. In progress; target 2026-06-15. **S**
- Anticoagulation that is safe and taken as prescribed, without major bleeding. In progress; target 2026-08-24. **S**
- Keep playing the piano and composing. In progress; target 2026-06-15. **S**

## Medication changes

- Stopped: Clopidogrel 75 mg oral tablet, one tablet daily, after a 300 mg loading dose in the emergency department **S**
- Started: Apixaban 5 mg oral tablet, one tablet twice daily **S**

## Guideline basis

- 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association (2021), American Heart Association and American Stroke Association (Stroke 2021;52(7):e364-e467)
- 2024 ACC Expert Consensus Decision Pathway on Practical Approaches for Arrhythmia Monitoring After Stroke (2024), American College of Cardiology (J Am Coll Cardiol 2025;85(6):657-681)
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023), American College of Cardiology, American Heart Association, American College of Chest Physicians and Heart Rhythm Society (Circulation 2024;149(1):e1-e156)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, atrial fibrillation and hypertension monographs (2026), Aether Forge
- Signs and Symptoms of Stroke (2026), Centers for Disease Control and Prevention
- Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026), Ke Ola Mamo

## Follow-up

- Three-month review in eight weeks. Call for bleeding that will not stop, black stools or any fall with a blow to the head; call 911 for any BE FAST sign. **S**
- Next scheduled visit 2026-06-15: three-month review after the stroke: function, mood, blood pressure, apixaban safety and falls. **S**
